JP2023526590A5 - - Google Patents

Info

Publication number
JP2023526590A5
JP2023526590A5 JP2022569031A JP2022569031A JP2023526590A5 JP 2023526590 A5 JP2023526590 A5 JP 2023526590A5 JP 2022569031 A JP2022569031 A JP 2022569031A JP 2022569031 A JP2022569031 A JP 2022569031A JP 2023526590 A5 JP2023526590 A5 JP 2023526590A5
Authority
JP
Japan
Prior art keywords
subject
level
agent according
actriib ligand
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526590A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032434 external-priority patent/WO2021231851A1/en
Publication of JP2023526590A publication Critical patent/JP2023526590A/ja
Publication of JP2023526590A5 publication Critical patent/JP2023526590A5/ja
Pending legal-status Critical Current

Links

JP2022569031A 2020-05-15 2021-05-14 ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物 Pending JP2023526590A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025955P 2020-05-15 2020-05-15
US63/025,955 2020-05-15
PCT/US2021/032434 WO2021231851A1 (en) 2020-05-15 2021-05-14 Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors

Publications (2)

Publication Number Publication Date
JP2023526590A JP2023526590A (ja) 2023-06-22
JP2023526590A5 true JP2023526590A5 (https=) 2024-05-22

Family

ID=78525025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569031A Pending JP2023526590A (ja) 2020-05-15 2021-05-14 ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物

Country Status (11)

Country Link
US (1) US20230210827A1 (https=)
EP (2) EP4649961A3 (https=)
JP (1) JP2023526590A (https=)
KR (1) KR20230010641A (https=)
CN (1) CN115551487A (https=)
AU (1) AU2021273065A1 (https=)
BR (1) BR112022022830A2 (https=)
CA (1) CA3177632A1 (https=)
IL (1) IL298156A (https=)
MX (1) MX2022014080A (https=)
WO (1) WO2021231851A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
CN104968801B (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CA3001654A1 (en) * 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
MA45811A (fr) * 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
WO2018185341A1 (en) * 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
PL3638243T3 (pl) * 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości
EP4041243A4 (en) * 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE

Similar Documents

Publication Publication Date Title
Johnson et al. Erythropoiesis‐stimulating agent hyporesponsiveness
CN1713926B (zh) 腹膜透析法
Paesano et al. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women
Sessler et al. New concepts in sepsis
CN104884055A (zh) 柠檬酸铁在治疗慢性肾脏疾病患者中的应用
Kuragano et al. Effects of Acetate‐Free Citrate‐Containing Dialysate on Metabolic Acidosis, Anemia, and Malnutrition in Hemodialysis Patients
JP2023526590A5 (https=)
JP2022518507A5 (https=)
JP2021169525A (ja) 可溶性ピロリン酸第二鉄を用いて鉄欠乏症を治療する方法
US20090306002A1 (en) Iron metabolism-improving agent
Suega et al. Profile of anemia in chronic renal failure patients: comparison between predialyzed and dialyzed patients at the Division of Nephrology, Department of Internal Medicine, Sanglah Hospital, Denpasar, Bali, Indonesia
CA3159368A1 (en) Therapeutic methods using vadadustat
Huang et al. Acute abrin poisoning treated with continuous renal replacement therapy and hemoperfusion successfully: a case report
Jung et al. Mycophenolic acid trough concentration and dose are associated with hematologic abnormalities but not rejection in kidney transplant recipients
Takeda et al. Cupric sulfate intoxication with rhabdomyolysis, treated with chelating agents and blood purification
US20230181688A1 (en) Methods for treating plasma protein imbalances or depletion
Vernon et al. Poisoning and drug overdose
Socha-Banasiak et al. Metallothioneins in inflammatory bowel diseases: Importance in pathogenesis and potential therapy target
Sheikhi et al. Cardiac surgery anesthesia and systemic inflammatory response
JP2023523568A5 (https=)
Higgins et al. Anemia in hemodialysis patients: changing concepts in management
JP6578293B2 (ja) 反応性が低下した患者のエリトロポエチン刺激剤の用量を減少させる方法
Liu et al. Acute self-induced poisoning with sodium ferrocyanide and methanol treated with plasmapheresis and continuous renal replacement therapy successfully: a case report
Insiripong et al. Iron deficiency anemia masking hemoglobin H disease: a case report
Murray et al. Current and future therapy in haemochromatosis and Wilson’s disease